A New Paradigm in Drug Development - The mission of Bio-Path is to make its neutral lipid delivery the standard delivery technology for antisense therapeutics in the pharmaceutical industry.
Liposomal Grb-2 Clinical Trial

Bio-Path completed six cohorts of the Phase I clinical trial evaluating Liposomal Grb-2 in blood cancers. The drug’s safety profile continues to be favorable with no treatment-related serious adverse events reported and data suggests possible anti-leukemia activity. A maximum tolerated dose has yet to be reached. The clinical trial is being conducted at the MD Anderson Cancer Center.

Patients are currently being enrolled into a safety segment of a Phase II program evaluating Liposomal Grb-2 in combination with Ara-C for AML.

Latest News

Nov 12, 2015
Definitive Proxy Statement

Definitive Additional Materials

Nov 10, 2015
Bio-Path Holdings Reports Third Quarter 2015 Operational and Financial Results

Nov 5, 2015
Bio-Path Holdings’ Data to be Presented at 57th American Society of Hematology (ASH) Annual Meeting

Jorge Cortes, M.D., of MD Anderson Cancer Center to present poster with data from Phase I and Ib clinical trials of BP-100-1.01 (Liposomal Grb-2 antisense) in blood cancers
Patient in Phase 1b combination therapy trial achieved complete remissio

Oct 13, 2015
Bio-Path Holdings to Present at the 14th Annual BIO Investor Forum - Tuesday, Oct 20, 2015 3:30 p.m. Pacific Time

Webcast Link to Conference Here (Tues. Oct 20, 3:30 Pacific Time)

Oct 9, 2015
Bio-Path Holdings Announces Successful Completion of Cohort 7 of Phase Ib of Clinical Trial Evaluating Liposomal Grb-2 in Acute Myeloid Leukemia